Status:
APPROVED_FOR_MARKETING
Treatment Use Study With Sunitinib (SU011248) For Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
18+ years
Brief Summary
The primary objective of this protocol is to provide access to SU011248 treatment for patients with metastatic RCC who are ineligible for participation in ongoing SU011248 clinical studies and have th...
Detailed Description
Given that an Expanded Access study does not meet the definition of a controlled clinical investigation, and as such, is not considered an applicable drug clinical trial per NIH, Basic Results for suc...
Eligibility Criteria
Inclusion
- renal cell carcinoma that is not amendable to standard therapy with curative intent
Exclusion
- current treatment in another therapeutic clinical trial
Key Trial Info
Start Date :
July 1 2005
Trial Type :
EXPANDED_ACCESS
End Date :
November 1 2011
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00130897
Start Date
July 1 2005
End Date
November 1 2011
Last Update
March 9 2012
Active Locations (271)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Scottsdale, Arizona, United States, 85260
2
Pfizer Investigational Site
San Francisco, California, United States, 94115-2378
3
Pfizer Investigational Site
San Francisco, California, United States, 94115
4
Pfizer Investigational Site
Aurora, Colorado, United States, 80040-0510